Significant Multiplexing Benefits of Co-Diagnostics’ CoPrimer™ Tech Presented at PAG XXVIII
Co-Diagnostics’ CoPrimer platform, licensed by LGC,
The presentation, titled “CoPrimer Assays for Multiplex PCR,” described a study that involved developing several genotyping assays using BHQplex™ CoPrimer technology, the LGC,
Multiplex PCR (polymerase chain reaction) refers to interrogating a genetic sample for the presence of multiple targets (certain genetic sequences) at one time, instead of performing separate tests for each target. Multiplex PCR has several cost, throughput, and economical advantages over single-plex PCR reactions, which advantages increase with the plex level.
In addition to groundbreaking multiplex capabilities, Bayer’s presentation also highlighted the CoPrimer technology’s inherent flexibility for assay interchangeability, and its high degree of sensitivity and specificity in detecting DNA targets.
“With partners like LGC, including their globe-spanning footprint in over 200 countries, and validation from such an important force in the world of agriculture as Bayer, we believe that
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release may include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in certain verticals or markets, (iv) capital resources and runway needed to advance the Company’s products and markets, (v) increased sales in the near-term, (vi) flexibility in managing the Company’s balance sheet, (vii) anticipation of business expansion, and (viii) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Head of Investor Relations